1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Urological Cancer Therapeutics Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Xofigo (radium Ra 223 dichloride)
1.4.3 Jevtana (cabazitaxel)
1.4.4 Inlyta (axitinib)
1.4.5 Votrient (pazopanib hydrochloride)
1.4.6 Sutent (sunitinib malate)
1.4.7 Zytiga (abiraterone acetate)
1.4.8 Xtandi (enzalutamide)
1.4.9 Opdivo (nivolumab)
1.4.10 Provenge (sipuleucel-T)
1.5 Market by Application
1.5.1 Global Urological Cancer Therapeutics Drugs Market Share by Application: 2021-2026
1.5.2 Hospital
1.5.3 Medical Research Laboratory
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Urological Cancer Therapeutics Drugs Market
1.8.1 Global Urological Cancer Therapeutics Drugs Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Urological Cancer Therapeutics Drugs Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Urological Cancer Therapeutics Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Urological Cancer Therapeutics Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Urological Cancer Therapeutics Drugs Sales Volume Market Share by Region (2015-2020)
3.2 Global Urological Cancer Therapeutics Drugs Sales Revenue Market Share by Region (2015-2020)
3.3 North America Urological Cancer Therapeutics Drugs Sales Volume
3.3.1 North America Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.3.2 North America Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Urological Cancer Therapeutics Drugs Sales Volume
3.4.1 East Asia Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Urological Cancer Therapeutics Drugs Sales Volume (2015-2020)
3.5.1 Europe Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Urological Cancer Therapeutics Drugs Sales Volume (2015-2020)
3.6.1 South Asia Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Urological Cancer Therapeutics Drugs Sales Volume (2015-2020)
3.7.1 Southeast Asia Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Urological Cancer Therapeutics Drugs Sales Volume (2015-2020)
3.8.1 Middle East Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Urological Cancer Therapeutics Drugs Sales Volume (2015-2020)
3.9.1 Africa Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Urological Cancer Therapeutics Drugs Sales Volume (2015-2020)
3.10.1 Oceania Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Urological Cancer Therapeutics Drugs Sales Volume (2015-2020)
3.11.1 South America Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.11.2 South America Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Urological Cancer Therapeutics Drugs Sales Volume (2015-2020)
3.12.1 Rest of the World Urological Cancer Therapeutics Drugs Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Urological Cancer Therapeutics Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Urological Cancer Therapeutics Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Urological Cancer Therapeutics Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Urological Cancer Therapeutics Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Urological Cancer Therapeutics Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Urological Cancer Therapeutics Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Urological Cancer Therapeutics Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Urological Cancer Therapeutics Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Urological Cancer Therapeutics Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Urological Cancer Therapeutics Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Urological Cancer Therapeutics Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Urological Cancer Therapeutics Drugs Sales Volume Market Share by Type (2015-2020)
14.2 Global Urological Cancer Therapeutics Drugs Sales Revenue Market Share by Type (2015-2020)
14.3 Global Urological Cancer Therapeutics Drugs Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Urological Cancer Therapeutics Drugs Consumption Volume by Application (2015-2020)
15.2 Global Urological Cancer Therapeutics Drugs Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Urological Cancer Therapeutics Drugs Business
16.1 Novartis
16.1.1 Novartis Company Profile
16.1.2 Novartis Urological Cancer Therapeutics Drugs Product Specification
16.1.3 Novartis Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Celgene Corporation
16.2.1 Celgene Corporation Company Profile
16.2.2 Celgene Corporation Urological Cancer Therapeutics Drugs Product Specification
16.2.3 Celgene Corporation Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 AstraZeneca
16.3.1 AstraZeneca Company Profile
16.3.2 AstraZeneca Urological Cancer Therapeutics Drugs Product Specification
16.3.3 AstraZeneca Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Pfizer
16.4.1 Pfizer Company Profile
16.4.2 Pfizer Urological Cancer Therapeutics Drugs Product Specification
16.4.3 Pfizer Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Abbott Laboratories
16.5.1 Abbott Laboratories Company Profile
16.5.2 Abbott Laboratories Urological Cancer Therapeutics Drugs Product Specification
16.5.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Johnson & Johnson
16.6.1 Johnson & Johnson Company Profile
16.6.2 Johnson & Johnson Urological Cancer Therapeutics Drugs Product Specification
16.6.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Ferring Pharmaceuticals
16.7.1 Ferring Pharmaceuticals Company Profile
16.7.2 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Specification
16.7.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Bristol-Myers Squibb
16.8.1 Bristol-Myers Squibb Company Profile
16.8.2 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Specification
16.8.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Astellas
16.9.1 Astellas Company Profile
16.9.2 Astellas Urological Cancer Therapeutics Drugs Product Specification
16.9.3 Astellas Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Dendreon Corporation
16.10.1 Dendreon Corporation Company Profile
16.10.2 Dendreon Corporation Urological Cancer Therapeutics Drugs Product Specification
16.10.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Sanofi S.A.
16.11.1 Sanofi S.A. Company Profile
16.11.2 Sanofi S.A. Urological Cancer Therapeutics Drugs Product Specification
16.11.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 GlaxoSmithKline plc
16.12.1 GlaxoSmithKline plc Company Profile
16.12.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Specification
16.12.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 Roche Healthcare
16.13.1 Roche Healthcare Company Profile
16.13.2 Roche Healthcare Urological Cancer Therapeutics Drugs Product Specification
16.13.3 Roche Healthcare Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Indevus Pharmaceuticals Inc
16.14.1 Indevus Pharmaceuticals Inc Company Profile
16.14.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Specification
16.14.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 Ipsen
16.15.1 Ipsen Company Profile
16.15.2 Ipsen Urological Cancer Therapeutics Drugs Product Specification
16.15.3 Ipsen Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Urological Cancer Therapeutics Drugs Manufacturing Cost Analysis
17.1 Urological Cancer Therapeutics Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
17.4 Urological Cancer Therapeutics Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Urological Cancer Therapeutics Drugs Distributors List
18.3 Urological Cancer Therapeutics Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Urological Cancer Therapeutics Drugs (2021-2026)
20.2 Global Forecasted Revenue of Urological Cancer Therapeutics Drugs (2021-2026)
20.3 Global Forecasted Price of Urological Cancer Therapeutics Drugs (2015-2026)
20.4 Global Forecasted Production of Urological Cancer Therapeutics Drugs by Region (2021-2026)
20.4.1 North America Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.4.3 Europe Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.4.7 Africa Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.4.9 South America Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Urological Cancer Therapeutics Drugs by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country
21.2 East Asia Market Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country
21.3 Europe Market Forecasted Consumption of Urological Cancer Therapeutics Drugs by Countriy
21.4 South Asia Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country
21.5 Southeast Asia Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country
21.6 Middle East Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country
21.7 Africa Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country
21.8 Oceania Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country
21.9 South America Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country
21.10 Rest of the world Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer